Characteristics of the 321 patients*
Characteristic, no. (%) . | CVP, no. (%) . | R-CVP, no. (%) . |
|---|---|---|
| No. | 159 | 162 |
| Age | ||
| Younger than 40 y | 16 (10) | 24 (15) |
| 40-50 y | 45 (28) | 48 (30) |
| 51-60 y | 54 (34) | 49 (30) |
| 60 y or older | 44 (28) | 41 (25) |
| Median | 53 | 52 |
| Male sex | 85 (54) | 88 (54) |
| Performance status (ECOG score)† | ||
| 0 | 90 (57) | 93 (57) |
| 1 | 60 (38) | 65 (40) |
| Greater than 1 | 8 (5) | 4 (3) |
| Not evaluable/missing | 1 (1) | 0 |
| Histology class (IWF classification) | ||
| Local review | ||
| A (CLL) | 2 (1) | 0 |
| B (FL grade 1) | 53 (33) | 59 (36) |
| C (FL grade 2) | 89 (56) | 87 (54) |
| D (FL grade 3) | 13 (8) | 14 (9) |
| Other | 1 (1) | 1 (1) |
| Not evaluable/missing | 1 (1) | 1 (1) |
| Central review | ||
| A (CLL) | 2 (1) | 0 |
| B (FL grade 1) | 46 (29) | 38 (23) |
| C (FL grade 2) | 69 (43) | 82 (51) |
| D (FL grade 3) | 19 (12) | 19 (12) |
| Other | 6 (4) | 7 (4) |
| Not evaluable/missing | 17 (11) | 16 (10) |
| Stage (Ann Arbor) | ||
| II | 2 (1) | 2 (1) |
| III-1∥ | 4 (3) | 5 (3) |
| III-2¶ | 41 (26) | 40 (25) |
| IV | 112 (70) | 114 (70) |
| Not evaluable/missing | 0 | 1 (1) |
| International Prognostic Index score§ | ||
| 0 | 1 (1) | 1 (1) |
| 1 | 69 (43) | 72 (44) |
| 2 | 57 (36) | 57 (35) |
| 3 | 21 (13) | 19 (12) |
| 4 | 3 (2) | 2 (1) |
| Not evaluable/missing | 8 (5) | 11 (7) |
| Follicular Lymphoma International Prognostic Index score | ||
| 0-2 | 75 (47) | 80 (49) |
| 3-5 | 75 (47) | 71 (44) |
| Not evaluable/missing | 9 (6) | 11 (7) |
| 1 or more B symptoms‡ | 51 (32) | 65 (40) |
| Bulky disease | 73 (46) | 63 (39) |
| Bone marrow involvement | 102 (64) | 103 (64) |
| 1 or more extranodal sites | 27 (17) | 28 (17) |
| Elevated LDH | 39 (26) | 39 (26) |
Characteristic, no. (%) . | CVP, no. (%) . | R-CVP, no. (%) . |
|---|---|---|
| No. | 159 | 162 |
| Age | ||
| Younger than 40 y | 16 (10) | 24 (15) |
| 40-50 y | 45 (28) | 48 (30) |
| 51-60 y | 54 (34) | 49 (30) |
| 60 y or older | 44 (28) | 41 (25) |
| Median | 53 | 52 |
| Male sex | 85 (54) | 88 (54) |
| Performance status (ECOG score)† | ||
| 0 | 90 (57) | 93 (57) |
| 1 | 60 (38) | 65 (40) |
| Greater than 1 | 8 (5) | 4 (3) |
| Not evaluable/missing | 1 (1) | 0 |
| Histology class (IWF classification) | ||
| Local review | ||
| A (CLL) | 2 (1) | 0 |
| B (FL grade 1) | 53 (33) | 59 (36) |
| C (FL grade 2) | 89 (56) | 87 (54) |
| D (FL grade 3) | 13 (8) | 14 (9) |
| Other | 1 (1) | 1 (1) |
| Not evaluable/missing | 1 (1) | 1 (1) |
| Central review | ||
| A (CLL) | 2 (1) | 0 |
| B (FL grade 1) | 46 (29) | 38 (23) |
| C (FL grade 2) | 69 (43) | 82 (51) |
| D (FL grade 3) | 19 (12) | 19 (12) |
| Other | 6 (4) | 7 (4) |
| Not evaluable/missing | 17 (11) | 16 (10) |
| Stage (Ann Arbor) | ||
| II | 2 (1) | 2 (1) |
| III-1∥ | 4 (3) | 5 (3) |
| III-2¶ | 41 (26) | 40 (25) |
| IV | 112 (70) | 114 (70) |
| Not evaluable/missing | 0 | 1 (1) |
| International Prognostic Index score§ | ||
| 0 | 1 (1) | 1 (1) |
| 1 | 69 (43) | 72 (44) |
| 2 | 57 (36) | 57 (35) |
| 3 | 21 (13) | 19 (12) |
| 4 | 3 (2) | 2 (1) |
| Not evaluable/missing | 8 (5) | 11 (7) |
| Follicular Lymphoma International Prognostic Index score | ||
| 0-2 | 75 (47) | 80 (49) |
| 3-5 | 75 (47) | 71 (44) |
| Not evaluable/missing | 9 (6) | 11 (7) |
| 1 or more B symptoms‡ | 51 (32) | 65 (40) |
| Bulky disease | 73 (46) | 63 (39) |
| Bone marrow involvement | 102 (64) | 103 (64) |
| 1 or more extranodal sites | 27 (17) | 28 (17) |
| Elevated LDH | 39 (26) | 39 (26) |
IWF indicates international working formulation; CLL, chronic lymphocytic leukemia; CVP, cyclophosphamide, vincristine, and prednisone; FL, follicular lymphoma; and LDH, lactate dehydrogenase.
Percentages based on evaluable patients.
Performance status was defined according to the criteria of the Eastern Clinical Oncology Group. A higher score indicates poorer performance status.
B symptoms were defined as fever, weight loss, and night sweats.
Higher scores indicate a greater risk of death.
Stage III-1: Involvement of lymph nodes on both sides of diaphragm. Abdominal disease limited to the upper abdomen (ie, spleen, splenic hilar nodes, celiac nodes, porta hepatica node).
Stage III-2: Involvement of lymph nodes on both sides of diaphragm. Abdominal disease including para-aortic, mesenteric, and iliac involvement with or without disease in the upper abdomen.